OR WAIT null SECS
Dr. Ross J. Horsburgh brings 20 Years of pharmaceutical and CRO experience in Asia/Pacific region to key leadership role.
Cincinnati, OH-January 16, 2008— Kendle (www.kendle.com), a leading, global full-service clinical research organization (CRO), today announced Dr. Ross J. Horsburgh has joined the company as vice president, global clinical development–Asia/Pacific. In this role, he will lead the company’s overall expansion in Asia/Pacific and will provide strategic oversight for its Phase II–III operations in the region, including Melbourne and Sydney, Australia; New Delhi, India; and Beijing, China. In all, Dr. Horsburgh brings 20 years of CRO and pharmaceutical industry experience to Kendle.
“With a population base of nearly 4.0 billion and R&D spending expected to reach $20 billion by 2013, Asia/Pacific is recognized by our customers as one of the more dynamic regions in which to conduct clinical trials,” said Dr. Kendle. “Dr. Horsburgh’s extensive clinical development experience and familiarity with the Asia/Pacific region will benefit both our customers and Kendle as we execute on our growth strategy for this pivotal market.”
Prior to joining Kendle, Dr. Horsburgh was regional medical director, Asia Pacific for AstraZeneca. In this role, he assembled and led a team of 200 individuals across 13 markets. He also served as head of AstraZeneca’s internal clinical research organization, responsible for quality assurance, drug safety, talent management and development, input of the Asian view into global product design, and ultimately, submissions to the U.S. Food and Drug Administration and the European Medicines Agency. Prior to AstraZeneca, Dr. Horsburgh held positions with Ciba and the Auckland Hospital Board. He earned his medical degree from the University of Auckland and his master’s and bachelor’s degrees from the University of Canterbury.
Dr. Horsburgh will report directly to Dr. Kendle for Asia/Pacific expansion and to Martha Feller, senior vice president, global clinical development for Phase II–III operations. He will be based in Singapore.